Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Clinical trial NCT04622566 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT04622566
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-30
- Primary completion
- 2021-12-30
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.